ArticleGastro hep advances2025
Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Discordant FIB-4 and liver stiffness in metabolic dysfunction-associated steatotic liver disease as related to histology and liver-related events in a global cohort: Editorial on "Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement".Clinical and molecular hepatology · 2026Article
- Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus.Hormones (Athens, Greece) · 2026Review
- A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.Diabetes, obesity & metabolism · 2025Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: This study assessed the relationship between Fibrosis-4 (FIB-4) scores at time of initial metabolic dysfunction-associated steatohepatitis (MASH) diagnosis, as well as subsequent changes in these scores over time, and any adverse hepatic and extrahepatic outcomes. Methods: This study retrospectively analyzed administrative claims data from patients with a MASH diagnosis between 2015 and 2022. Patients were categorized based on risk of advanced fibrosis (low, indeterminate, and high) using FIB-4 score calculated at index (date of FIB-4 score within ±180 days of MASH diagnosis) and longitudinally. Adjusted hazard ratios (aHRs) and confidence intervals (CIs) were estimated to determine associations between index and longitudinal changes in FIB-4, and hazard of major adverse liver outcomes (MALO) and major adverse cardiovascular events (2-point assessment; MACE-2pt). Results: A total of 17,511 and 19,395 patients with an index FIB-4 score were included in the MALO and MACE-2pt analyses, respectively. Cohorts with longitudinal FIB-4 scores comprised 10,655 and 11,934 patients for the 2 respective outcomes. High-risk FIB-4 score at index was significantly associated with higher hazard of MALO (aHR: 4.29; 95% CI: 3.87-4.77) and MACE-2pt (aHR: 1.44; 95% CI: 1.25-1.66) compared with low risk. Progression from low-risk to high-risk FIB-4 score was associated with a higher hazard of MALO (aHR: 2.62; 95% CI: 1.92-3.58), vs remaining at low risk. This was also found for progression from indeterminate-risk to high-risk FIB-4 score (aHR: 1.94; 95% CI: 1.50-2.53). Conclusion: High-risk index FIB-4 and increases in FIB-4 are associated with increased hazard of MALO and MACE. Thus, in patients diagnosed with MASH, FIB-4 scores could serve as an important noninvasive and prognostic tool for adverse cardiovascular and liver outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.